
Biogen’s Growth Products Surge 12% as Q1 Earnings Per Share Jump 18%
Biogen Inc.Description
What this story covers
Biogen’s Q1 2026 results show a 2% revenue increase and 18% EPS growth, driven by a 12% rise in new growth products. Despite higher R&D spending and revised guidance for acquisitions, robust cash flow supports its strategic transition.
Story snapshot
CompanyBiogen Inc.
TickerBIIB
VariantStandard detailed
Duration5:17
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000875045-26-000042
Sources1
Full Story Script
Content not available for this story.